Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation

Read full text Summarise with VIRAT
Authors: Jessica N. Schlatter, Wei Wei, Yingying Chen, Annick Melse, Yong Wang, Sara Guerra, José Oberholzer
Cited by: 0
References: 183

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains highly resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment. Interleukin-12 (IL-12), a potent immunostimulatory cytokine, has demonstrated remarkable therapeutic potential across a range of malignancies. However, systemic administration of IL-12 has been linked to severe dose-limiting toxicities, including cytokine release syndrome and multi-organ dysfunction, representing a persistent barrier to clinical translation. This review examines the rationale for IL-12-based immunotherapy in PDAC, synthesizing the current knowledge on immunotherapy approaches for this disease, IL-12's mechanisms of action in cancer treatment, and synergistic combination strategies. We describe three major delivery platforms that have emerged to overcome the limitations of systemic delivery due to toxicity: cellular encapsulation systems, virotherapy-mediated approaches, lipid nanocapsule formulations, polymer-based platforms, local electroporation-mediated transfection, and CAR-T combined therapy. These innovative strategies enable localized, sustained IL-12 expression within the tumor microenvironment while minimizing systemic exposure and associated toxicities. By safely harnessing IL-12's potent immunostimulatory properties, these next-generation delivery systems offer promising therapeutic avenues for PDAC and other immunotherapy-resistant malignancies.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1755796–1755796
Publication date
25 March 2026
Language
EN